FACCHINETTI, FRANCESCO
 Distribuzione geografica
Continente #
NA - Nord America 575
EU - Europa 442
AS - Asia 111
Totale 1.128
Nazione #
US - Stati Uniti d'America 570
SE - Svezia 159
IE - Irlanda 132
CN - Cina 82
IT - Italia 76
DE - Germania 28
AT - Austria 17
IN - India 10
TR - Turchia 8
GB - Regno Unito 6
CA - Canada 5
FI - Finlandia 4
FR - Francia 4
SG - Singapore 4
AL - Albania 3
BE - Belgio 3
IL - Israele 2
JP - Giappone 2
KH - Cambogia 2
RU - Federazione Russa 2
UA - Ucraina 2
CH - Svizzera 1
ES - Italia 1
HK - Hong Kong 1
LU - Lussemburgo 1
NL - Olanda 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 1.128
Città #
Chandler 195
Dublin 129
Ashburn 48
New York 44
Ann Arbor 35
Shanghai 27
Princeton 23
Bremen 20
Vienna 17
Dearborn 14
Des Moines 12
Parma 12
Wilmington 11
Beijing 8
Nanjing 8
Pune 7
Boardman 6
Izmir 5
Milan 5
Bologna 4
Busseto 4
Changsha 4
Helsinki 4
Kunming 4
Nanchang 4
Pavia 4
Brussels 3
Fremont 3
Grafing 3
Hebei 3
Jinan 3
Nanning 3
Naples 3
Redwood City 3
Tirana 3
Washington 3
Woodbridge 3
Candiac 2
Fairfield 2
Foligno 2
Guangzhou 2
Houston 2
Istanbul 2
Jiaxing 2
Minerbio 2
Norwalk 2
Reggio Emilia 2
Rome 2
Trento 2
West Jordan 2
Andover 1
Bangalore 1
Bordeaux 1
Borås 1
Bucharest 1
Cambridge 1
Dolianova 1
Florence 1
Hangzhou 1
Hefei 1
Kingston 1
Kocaeli 1
Lanzhou 1
Los Angeles 1
Luxembourg 1
Macomer 1
Ningbo 1
Pavullo Nel Frignano 1
Redmond 1
Rockville 1
Saint Petersburg 1
San Mateo 1
Santa Coloma de Gramenet 1
Shenyang 1
Tappahannock 1
Wuhan 1
Zurich 1
Totale 740
Nome #
The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC 108
Widespread Nivolumab-induced Enteropathy in a Long Responder Non–Small-cell Lung Cancer Patient 93
Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature 70
YES1 and MYC Amplifications as Synergistic Resistance Mechanisms to Different Generation ALK Tyrosine Kinase Inhibitors in Advanced NSCLC: Brief Report of Clinical and Preclinical Proofs 63
Sarcoid-like reaction mimicking disease progression in an ALK-positive lung cancer patient receiving lorlatinib 60
PD-L1 ≥ 50% lung cancer refractory to PD-1 inhibition: The role of salvage chemo-immunotherapy combination 56
CEA serum level as early predictive marker of outcome during EGFR-TKI therapy in advanced NSCLC patients 55
Vascular liver injury mimicking an intrahepatic cholangiocarcinoma in a COVID-19 patient 55
Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition 53
CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors 53
First-line immunotherapy in non-small cell lung cancer patients with poor performance status: A systematic review and meta-analysis 47
Osimertinib in CNS-progressive EGFR-mutant lung cancer: do we need to detect T790M? 46
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors 44
Moving immune checkpoint blockade in thoracic tumors beyond NSCLC 43
Exploring the role of respiratory microbiome in lung cancer: A systematic review 43
Cystic brain metastases and RET fusion in lung cancer 43
Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy 41
Bilateral Severe Corneal Ulcer in a Patient with Lung Adenocarcinoma Treated with Gefitinib 39
Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: A systematic review and meta-analysis 38
Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non–small-cell Lung Cancer Progressing on Crizotinib 34
First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status 34
Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non–small Cell Lung Cancer 32
Upfront osimertinib in EGFR-mutated non-small cell lung cancer: is brain still a sanctuary? 22
Divergent PD-1 expression in tissue and circulating CD8 lymphocytes defines an immune profile predictive of the response to nivolumab in advanced NSCLC 6
Totale 1.178
Categoria #
all - tutte 4.690
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.690


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20198 0 0 0 0 0 0 0 0 0 1 6 1
2019/202097 21 15 2 6 12 12 11 6 4 5 0 3
2020/202164 1 0 4 8 7 5 1 8 13 6 9 2
2021/2022150 2 2 0 29 2 3 27 7 9 6 7 56
2022/2023619 81 76 38 56 45 77 23 31 164 6 21 1
2023/2024189 11 19 3 2 17 80 18 17 12 10 0 0
Totale 1.178